Browse News

Found 310 articles

• Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023

  9/27/2023

  Daxor Corporation announces it will be attending the Annual Scientific Meeting of the Heart Failure Society of America which brings together the world’s leading experts in heart failure at the Huntington Convention Center in Cleveland, Ohio from October 6-9, 2023.

• Daxor Corporation to Exhibit at the Medaxiom Cardiovascular Transforum Conference Fall’23 to Advance Awareness and Further Adoption of Daxor’s Blood Volume Diagnostic (BVA-100®)

  9/26/2023

  Daxor Corporation, the global leader in blood volume measurement technology, announces it will be exhibiting at the MedAxiom CV Transforum Fall’23 Conference being held at the JW Marriott in Austin, TX from October 5-7, 2023.

• Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients

  9/11/2023

  Daxor Corporation announced that the National Institutes of Health National Institute of General Medical Sciences has awarded the Company a $305K Phase I Small Business Innovative Research grant to support the development of the Sepsis FLO, a clinical decision support tool designed to precisely guide blood volume management and treatment in sepsis patients.

• Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  9/7/2023

  Daxor Corporation announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11 - 13, 2023 at the Lotte New York Palace.

• Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023

  8/28/2023

  Daxor Corporation, the global leader in blood volume measurement technology, announces it filed Form N-CSR disclosing its schedule of portfolio holdings for the six-months ended June 30, 2023.

• JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100®

  8/10/2023

  Daxor Corporation announces a research letter in the Journal of the American College of Cardiology – Heart Failure reporting on the successful results of a pilot 31 patient randomized control trial conducted by the Duke Clinical Research Institute utilizing Daxor’s BVA-100 diagnostic to measure clinician assessment accuracy and the impact of optimizing decongestion therapy for heart failure patients with the diagnostic.

• JACC-HF Study Compares Daxor’s BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients

  7/12/2023

  Daxor Corporation announces a new research letter in the Journal of the American College of Cardiology – Heart Failure validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients.

• Daxor Corporation Announces Further Acquisitions and Increased Utilization of its BVA-100® Blood Volume Diagnostic Throughout the U.S.

  7/11/2023

  Daxor Corporation today announces expansion of blood volume analysis (BVA) into five of six hospitals in the Southeast and increased utilization for clinical use at two sites to guide fluid management in patients during the second quarter of 2023.

• Daxor Corporation Awarded $1.1 Million Contract from the United States Defense Health Agency for Added Capabilities to its Point-of-Care Blood Volume Analyzer

  7/5/2023

  Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced that the United States Defense Health Agency (DHA) has awarded the Company a $1.1 million sequential Phase II Small Business Innovative Research (SBIR) contract to add the capability of electronic medical record (EMR) integration to its small, portable, highly accurate, battery-powered blood volume analyzer.

• Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering

  6/22/2023

  Daxor Corporation announced that Maxim Group LLC, as Representative of several Underwriters of its previously announced secondary public offering have partially exercised their option to purchase an additional 54,339 Option Shares of Daxor’s Class A common stock at a public price of $9.75 per share.

• Daxor Corporation to Showcase the Benefits of BVA-100® Guided Care at the American Association of Heart Failure Nurses (AAHFN) 19th Annual Meeting

  6/20/2023

  Daxor Corporation announces today it will exhibit at the American Association of Heart Failure Nurses (AAHFN) 19 th Annual Meeting from June 29 - July 1, 2023 at the Boston Marriott Copley Place.

• Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services

  6/15/2023

  Daxor Corporation announces the launch of a new service designed to drive faster adoption and provide greater prescriber access to Daxor’s innovative blood volume analysis technology.

• Daxor Corporation to Participate in the Maxim Group Virtual Healthcare Conference

  6/12/2023

  Daxor Corporation, the global leader in blood volume measurement technology, announced that Michael Feldschuh, CEO and President has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest.

• Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering

  5/25/2023

  DAXOR CORPORATION, the global leader in blood volume measurement technology, announced the closing of its previously announced underwritten public offering of 410,260 shares of its common stock at a public offering price of $9.75 per share.

• Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering

  5/22/2023

  DAXOR CORPORATION today announced the pricing of its previously announced underwritten public offering of 410,260 shares of its common stock at a public offering price of $9.75 per share. Gross proceeds from the offering are expected to be approximately $4.0 million before deducting underwriting discounts, commissions, and estimated offering expenses.

• Daxor Corporation Announces Proposed Underwritten Public Offering - May 19, 2023

  5/19/2023

  DAXOR CORPORATION, the global leader in blood volume measurement technology, announces that it has commenced an underwritten public offering of shares of its common stock.

• New Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes

  5/18/2023

  Daxor Corporation(Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure patients published in the European Society of Cardiology Heart Failure.

• New Studies Presented at the 43rd International Society for Heart and Lung Transplant Validate the Applicability of the BVA-100® Blood Test for Patients with Advanced Heart Failure

  4/20/2023

  Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke University Medical Center validating the benefits of the Company’s BVA-100 blood test in optimizing individualized therapy for advanced heart failure patients.

• Daxor Corporation to Exhibit at the MedAxiom Cardiovascular Transforum Conference Spring’23 to Advance Awareness and Further Adoption of Daxor’s Blood Volume Diagnostic (BVA-100®)

  4/17/2023

  Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring’23 Conference being held at the Renaissance Orlando at SeaWorld in Orlando, FL from April 20-22, 2023.

• Daxor Corporation to Exhibit at the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

  4/13/2023

  Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be attending the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions, which brings together the world’s leading experts in heart and lung transplant being held at the Colorado Convention Center, from April 19-22, in Denver, CO.